Exhibit 3

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of Keros Therapeutics, Inc., and that this Agreement be included as an Exhibit to such joint filing. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, each of the undersigned hereby executes this Agreement as of this 17th day of February, 2026.

	D. E. Shaw & Co., L.P.

	By:	/s/ Daniel R. Marcus
		Daniel R. Marcus
		Chief Compliance Officer

	D. E. Shaw & Co., L.L.C.

	By:	/s/ Daniel R. Marcus
		Daniel R. Marcus
		Authorized Signatory

	David E. Shaw

	By:	/s/ Daniel R. Marcus
		Daniel R. Marcus
		Attorney-in-Fact for David E. Shaw

Keros Therapeutics, Inc. SCHEDULE 13G/A